Abstract
Osteoporosis affects more than 200 million peo� ple worldwide [1] and its prevalence is expected to increase along with an aging population. The overall lifetime risk of an osteoporotic fracture is approximately 50% for women and 20% for men [2], which is comparable to that of cardio � which is comparable to that of cardio� vascular disease and higher than that of cancers, including breast cancer. Bisphosphonates repre� sent the mainstay of osteoporosis management. The results of several controlled clinical trials have shown that treatment with bisphospho� nates increases bone mineral density, reduces bone resorption and hence decreases the risk of osteoporotic fractures [3]. However, the efficacy observed in clinical trials does not translate to
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
